GC Biopharma Announces Lunch Symposium and Poster Presentations on IVIG Product Characterization at the 2026 CIS Annual Meeting

About this update from Gc Biopharma Corp.

Presentations describe molecular size distribution of ALYGLO® after mechanical stress, as well as cross-product analyses of viscosity and immunogenicity-related contaminant protein profiles TEANECK, N.J., May 04, 2026--(BUSINESS WIRE)--GC Biopharma USA, Inc., a leader in plasma-derived products, announced today that it will host a lunch symposium and support three scientific presentations at the 2026 Clinical Immunology Society (CIS) Annual Meeting, taking place May 6 to 9 in New Orleans, Louisiana. GC Biopharma’s presentations at CIS will include two company-authored posters and one EpiVax-led poster supported through GC Biopharma’s Investigator-Initiated Research Program. GC Biopharma’s two posters will present research on molecular size distribution of ALYGLO® (immune globulin intravenous, human-stwk, 10% liquid) following mechanical stress and on viscosity across IVIG products. The EpiVax-led poster will present an initial in silico evaluation of contaminant protein signatures and predicted immunogenicity-related differences across four commercially available IVIG products. "These presentations reflect GC Biopharma’s commitment to advancing scientific understanding of IVIG characterization through both company-led research and support for externally led studies that explore complementary product attributes," said Stacey Ness, PharmD, IgCP, CSP, MSCS, AAHIVP, Medical Science Liaison, Medical Affairs, GC Biopharma USA. "Together, they represent several approaches to characterizing IVIG products with potential relevance to clinical practice." GC Biopharma’s lunch symposium, titled "From Molecules to Tolerability: Understanding Immunoglobulins and Immunogenicity Through Advanced Molecular Characterization," will take place on Friday, May 8, from 1:10 p.m. to 2:10 p.m. CT. The session will bring together expertise in advanced protein characterization and immunogenicity assessment to explore how analytical methods may deepen scientific understanding of immunoglobulin products. The speakers for this session will be: Poster presentations at CIS will include two studies conducted by GC Biopharma and one externally led study from EpiVax supported through GC Biopharma’s Investigator-Initiated Research Program: Title: Foundational Analysis of the Impact of Mechanical Stress on Molecular Size Distribution in Immune Globulin Intravenou...

View stock analysis, news, and events for Gc Biopharma Corp.